ANAGRELIDE HYDROCHLORIDE by Cipla is unknown. Approved for thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and 2 more indications. First approved in 2005.
Drug data last refreshed 18h ago
unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
Worked on ANAGRELIDE HYDROCHLORIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments